GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spago Nanomedical AB (FRA:7UX) » Definitions » ROE % Adjusted to Book Value

Spago Nanomedical AB (FRA:7UX) ROE % Adjusted to Book Value : -46.91% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Spago Nanomedical AB ROE % Adjusted to Book Value?

Spago Nanomedical AB's ROE % for the quarter that ended in Mar. 2024 was -81.63%. Spago Nanomedical AB's PB Ratio for the quarter that ended in Mar. 2024 was 1.74. Spago Nanomedical AB's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 was -46.91%.


Spago Nanomedical AB ROE % Adjusted to Book Value Historical Data

The historical data trend for Spago Nanomedical AB's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spago Nanomedical AB ROE % Adjusted to Book Value Chart

Spago Nanomedical AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -28.58 -73.52 -27.06

Spago Nanomedical AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -81.10 -52.21 -82.45 -39.86 -46.91

Competitive Comparison of Spago Nanomedical AB's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Spago Nanomedical AB's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spago Nanomedical AB's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spago Nanomedical AB's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Spago Nanomedical AB's ROE % Adjusted to Book Value falls into.



Spago Nanomedical AB ROE % Adjusted to Book Value Calculation

Spago Nanomedical AB's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-34.91% / 1.29
=-27.06%

Spago Nanomedical AB's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-81.63% / 1.74
=-46.91%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Spago Nanomedical AB ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Spago Nanomedical AB's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Spago Nanomedical AB (FRA:7UX) Business Description

Traded in Other Exchanges
Address
Scheelevagen 22, Lund, SWE, SE-223 63
Spago Nanomedical AB is a nanomedicine company in the field of cancer diagnosis and treatment. The company's product includes SpagoPix and Tumorad. The SpagoPix product aims to improve cancer diagnosis with magnetic resonance imaging through previous detection of tumors and metastases. The Tumorad products focuses on the development of a completely new form of radionuclide therapy for tumor selective radiation therapy of cancer. The company development projects are based on a platform of polymeric materials with varoious properties for precise diagnosis and treatment of life threatening and debilitating diseases.

Spago Nanomedical AB (FRA:7UX) Headlines

No Headlines